MARKET

ALT

ALT

Altimmune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.110
+0.070
+3.43%
After Hours: 2.110 0 0.00% 16:00 09/20 EDT
OPEN
2.020
PREV CLOSE
2.040
HIGH
2.140
LOW
2.020
VOLUME
120.50K
TURNOVER
--
52 WEEK HIGH
36.25
52 WEEK LOW
1.700
MARKET CAP
46.99M
P/E (TTM)
-0.3966
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ALT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ALT News

  • Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer
  • GlobeNewswire.09/09 12:00
  • 26 Stocks Moving in Thursday's Pre-Market Session
  • Benzinga.09/05 11:44
  • 25 Healthcare Stocks Moving In Wednesday's Pre-Market Session
  • Benzinga.08/21 12:48
  • Altimmune Announces $3.7 Million in Additional BARDA Funding to Advance NasoShield Clinical Development
  • GlobeNewswire.08/21 12:00

More

Industry

Biotechnology & Medical Research
+0.62%
Pharmaceuticals & Medical Research
+0.95%

Hot Stocks

Name
Price
%Change

About ALT

Altimmune Inc is a clinical-stage immunotherapeutics company. The Company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company’s product candidates include ALT-801, HepTcell, ALT-702, NasoVAX and NasoShield. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, its influenza vaccine candidate that stimulate multiple arms of the immune system and offers the potential to stop the infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is an intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine.
More

Webull offers Altimmune Inc (ALT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.